Company Profile

Kannalife Sciences Inc
Profile last edited on: 7/29/2019      CAGE: 6GHP8      UEI: R2W7XWC3KDB9

Business Identifier: Specialty biopharmaceutical company developing disruptive cannabinoid based therapeutics
Year Founded
2010
First Award
2018
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3805 Old Easton Road
Doylestown, PA 18902
   (516) 669-3219
   info@kannalife.com
   www.kannalife.com
Location: Multiple
Congr. District: 01
County: Bucks

Public Profile

Kannalife Sciences, Inc. (“Kannalife”), is a pharmaceutical and phyto-medical company involved in developmentof novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health “Cannabinoids as Antioxidants and Neuroprotectants” Kannalife is currently conducting R&D for a target drug candidate to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are both oxidative stress related diseases that affects the cognitive and behavioral functions, and the wellness of the brain. The firm is also conducting R&D on novel therapeutics to break the blood/brain barrier to be used for the treatment and prevention of oxidative and neuro-toxic stresses born from a variety of ailments and illnesses. With the objective of developing treatments to improve the quality of life of patients with neurodegenerative diseases, the firm's scientific team have background in phyto-medical, biological and pharmaceutical sciences with a long track record of successfully developing drugs from plant sources that are complex in nature and structure. Collectively, the team have published in over 300 notable journal publications and hold inventorships in over 65 patents. Our goal is to become a profitable and socially responsible company that de

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2023 2 NIH $3,270,688
Project Title: Development of KLS-13019 for Chemotherapy Induced Peripheral Neuropathy and Drug Dependence

Key People / Management

  Dean Petkanas -- Chairman & CEO

  Mark Corrao -- Chief Financial Officer

  Thoma Kikis -- Founder / Chief Communications Officer, Board Director

  William A Kinney -- Chief Scientific Officer

  Stuart W Titus -- Board Director

  Sara Jane Ward